Advertisement

Russian Journal of Genetics

, Volume 55, Issue 2, pp 238–245 | Cite as

Molecular and Genetic Study of Limb-Girdle Muscular Dystrophy 2D in Patient Cohorts with Various Forms of Progressive Muscular Dystrophies

  • M. V. BulakhEmail author
  • N. M. Galeeva
  • D. A. Polyakova
  • O. P. Ryzhkova
  • E. L. Dadali
  • A. V. PolyakovEmail author
HUMAN GENETICS
  • 4 Downloads

Abstract

Limb-girdle muscular dystrophy 2D (LGMD 2D) is the most common form of sarcoglycanopathies, which include autosomal recessive LGMDs caused by various molecular defects in the genes encoding sarcoglycan family proteins (α, β, γ, and δ). LGMD 2D occurs owing to mutations in the SGCA gene that encodes α-sarcoglycan. In general, it is difficult to distinguish clinical features of LGMD 2D from ones of both other pseudohypertrophic LGMDs and Duchenne/Becker muscular dystrophy (D/BMD). In the present paper, the study of LGMD 2D based on the analysis of the frequency of recurrent SGCA gene variants (c.229C>T, c.271G>A, and c.850C>T) in three patient cohorts with progressive muscular dystrophy manifesting itself after a normal motor development period was conducted. No LGMD 2D patients were found within the cohort of patients with clinical diagnosis of Emery–Dreifuss muscular dystrophy. The percentage of LGMD 2D patients was no less than 1.9% in the patient cohort with clinical diagnosis of LGMD, while LGMD 2D accounted for no less than 0.6% in the patient cohort with clinical diagnosis of D/BMD. It is noteworthy that, in these two cohorts, the most common SGCA variant in the world, c.229C>T, and a variant found in only one Italian family, c.271G>A, account for almost the same number of affected chromosomes. Therefore, LGMD 2D patients from Russia differ from LGMD 2D patients from all over the world in the presence of two major variants of this gene (c.229C>T and c.271G>A). The information value of the test system for the detection of three SGCA gene variants (the capability to reveal at least one mutant allele) was on average rather high (70% in the group of patients with LGMD and 50% in the group of patients with D/BMD); therefore this test system could be recommended as the primary step of LGMD 2D molecular diagnostics in patients with the corresponding clinical features.

Keywords:

LGMD 2D muscular dystrophy mutation spectrum SGCA sarcoglycanopathy 

Notes

COMPLIANCE WITH ETHICAL STANDARDS

Conflict of interests. The authors declare that they have no conflict of interest.

Statement of compliance with standards of research involving humans as subjects. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Informed consent for conducting the study was obtained from all patients, and in the case of minor patients, the consent was obtained from their parents or legal representatives.

REFERENCES

  1. 1.
    Davies, K.E. and Nowak, K.J., Molecular mechanisms of muscular dystrophies: old and new players, Nat. Rev. Mol. Cell Biol., 2006, vol. 7, no. 10, pp. 762—773.  https://doi.org/10.1038/nrm2024 CrossRefGoogle Scholar
  2. 2.
    Moore, S.A., Shilling, C.J., Westra, S., et al., Limb-girdle muscular dystrophy in the United States, J. Neuropathol. Exp. Neurol., 2006, vol. 65, no. 10, pp. 995—1003.  https://doi.org/10.1097/01.jnen.0000235854.77716.6c CrossRefGoogle Scholar
  3. 3.
    Meena, A.K., Sreenivas, D., Sundaram, C., et al., Sarcoglycanopathies: a clinico-pathological study, Neurol. India, 2007, vol. 55, no. 2, pp. 117—121.  https://doi.org/10.4103/0028-3886.32781 CrossRefGoogle Scholar
  4. 4.
    Ginjaar, H.B., van der Kooi, A.J., Ceelie, H., et al., Sarcoglycanopathies in Dutch patients with autosomal recessive limb girdle muscular dystrophy, J. Neurol., 2000, vol. 247, no. 7, pp. 524—529.CrossRefGoogle Scholar
  5. 5.
    Guglieri, M., Magri, F., D’Angelo, M.G., et al., Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients, Hum. Mutat., 2008, vol. 29, no. 2, pp. 258—266.  https://doi.org/10.1002/humu.20642 CrossRefGoogle Scholar
  6. 6.
    Duggan, D.J., Gorospe, J.R., Fanin, M., et al., Mutations in the sarcoglycan genes in patients with myopathy, N. Engl. J. Med., 1997, vol. 336, no. 9, pp. 618—624.  https://doi.org/10.1056/nejm199702273360904 CrossRefGoogle Scholar
  7. 7.
    Trabelsi, M., Kavian, N., Daoud, F., et al., Revised spectrum of mutations in sarcoglycanopathies, Eur. J. Hum. Genet., 2008, vol. 16, no. 7, pp. 793—803.  https://doi.org/10.1038/ejhg.2008.9 CrossRefGoogle Scholar
  8. 8.
    Roberds, S.L., Leturcq, F., Allamand, V., et al., Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy, Cell, 1994, vol. 78, no. 4, pp. 625—633.CrossRefGoogle Scholar
  9. 9.
    McNally, E.M., Yoshida, M., Mizuno, Y., et al., Human adhalin is alternatively spliced and the gene is located on chromosome 17q21, Proc. Natl. Acad. Sci. U.S.A., 1994, vol. 91, no. 21, pp. 9690—9694.CrossRefGoogle Scholar
  10. 10.
    Campbell, K.P., Adhalin gene mutations and autosomal recessive limb-girdle muscular dystrophy, Ann. Neurol., 1995. Sep., vol. 38, no. 3, pp. 353—354.  https://doi.org/10.1002/ana.410380302
  11. 11.
    Eymard, B., Romero, N.B., Leturcq, F., et al., Primary adhalinopathy (alpha-sarcoglycanopathy): clinical, pathologic, and genetic correlation in 20 patients with autosomal recessive muscular dystrophy, Neurology, 1997, vol. 48, no. 5, pp. 1227—1234.CrossRefGoogle Scholar
  12. 12.
    Shchagina, O.A., Polyakova, D.A., Ryzhkova, O.P., et al., Causes of muscular dystrophy in women with guiding diagnosis of Duchenne/Becker muscular dystrophy, Med. Genet., 2017, vol. 16, no. 11, pp. 17—22.Google Scholar
  13. 13.
    Moreira, E.S., Vainzof, M., Suzuki, O.T., et al., Genotype—phenotype correlations in 35 Brazilian families with sarcoglycanopathies including the description of three novel mutations, J. Med. Genet., 2003, vol. 40(2):E12.  https://doi.org/10.1136/jmg.40.2.e12 CrossRefGoogle Scholar
  14. 14.
    Hackman, P., Juvonen, V., Sarparanta, J., et al., Enrichment of the R77C alpha-sarcoglycan gene mutation in Finnish LGMD2D patients, Muscle Nerve, 2005, vol. 31, no. 2, pp. 199—204.  https://doi.org/10.1002/mus.20267 CrossRefGoogle Scholar
  15. 15.
    Carrie, A., Piccolo, F., Leturcq, F., et al., Mutational diversity and hot spots in the alpha-sarcoglycan gene in autosomal recessive muscular dystrophy (LGMD2D), J. Med. Genet., 1997, vol. 34, no. 6, pp. 470—475.CrossRefGoogle Scholar
  16. 16.
    http://mrc-holland.com.Google Scholar
  17. 17.
    http://provean.jcvi.org/index.php.Google Scholar
  18. 18.
    http://umd-predictor.eu/.Google Scholar
  19. 19.
    http://www.cbs.dtu.dk/services/NetGene2/.Google Scholar
  20. 20.
    http://genetics.bwh.harvard.edu/pph2/.Google Scholar
  21. 21.
    http://fathmm.biocompute.org.uk/.Google Scholar
  22. 22.
    Ryzhkova, O.P., Clinical and molecular genetic analysis of isolated limb—girdle muscular dystrophies, which are fermentopathies, Extended Abstract of Cand. Sci. Dissertation, 2011.Google Scholar
  23. 23.
    Adyan, T.A., Clinical and genetic diversity and the molecular diagnosis of Emery—Dreifuss muscular dystrophy, Extended Abstract of Cand. Sci. Dissertation, 2015.Google Scholar
  24. 24.
    Mahmood, O.A. and Jiang, X.M., Limb-girdle muscular dystrophies: where next after six decades from the first proposal (review), Mol. Med. Rep., 2014, vol. 9, no. 5, pp. 1515—1532.  https://doi.org/10.3892/mmr.2014.2048 CrossRefGoogle Scholar
  25. 25.
    Klinge, L., Dekomien, G., Aboumousa, A., et al., Sarcoglycanopathies: can muscle immunoanalysis predict the genotype?, Neuromuscul. Disord., 2008, vol. 18, no. 12, pp. 934—941.CrossRefGoogle Scholar
  26. 26.
    Babameto-Laku, A., Tabaku, M., Tashko, V., et al., The first case of primary alpha-sarcoglycanopathy identified in Albania, in two siblings with homozygous alpha-sarcoglycan mutation, Genet. Couns., 2011, vol. 22, no. 4, pp. 377—383.Google Scholar
  27. 27.
    Schara, U., Gencik, M., Mortier, J., et al., Alpha-sarcoglycanopathy previously misdiagnosed as Duchenne muscular dystrophy: implications for current diagnostics and patient care, Eur. J. Pediatr., 2001, vol. 160, no. 7, pp. 452—453.CrossRefGoogle Scholar
  28. 28.
    Xiong, H.Y., Alipanahi, B., Lee, L.J., et al., The human splicing code reveals new insights into the genetic determinants of disease, Science, 2015, vol. 347, no. 6218:1254806.  https://doi.org/10.1126/science.1254806 CrossRefGoogle Scholar
  29. 29.
    Ryzhkova, O.P., Kardymon, O.L., Prokhorchuk, E.B., et al., Guidelines for the interpretation of data obtained by the massive parallel sequencing (MPS) methods, Med. Genet., 2017, vol. 16, no. 7, pp. 4—17.Google Scholar

Copyright information

© Pleiades Publishing, Inc. 2019

Authors and Affiliations

  • M. V. Bulakh
    • 1
    Email author
  • N. M. Galeeva
    • 1
  • D. A. Polyakova
    • 1
  • O. P. Ryzhkova
    • 1
  • E. L. Dadali
    • 1
  • A. V. Polyakov
    • 1
    Email author
  1. 1.Research Centre for Medical GeneticsMoscowRussia

Personalised recommendations